Ajanta Pharma Ltd
About
Ajanta Pharma is an Indian pharmaceutical company with a global footprint, marking its presence in more than 30 countries all over the world. Its primary businesses include branded generics in India, generics in the USA, emerging markets of Asia and Africa, and institution sales in Africa. Its products come in multiple dosage forms like capsules, tablets, powders, ointments, eye drops, nasal sprays, etc. Ajanta’s offerings are concerned with therapeutic segments of dermatology, cardiology, ophthalmology, nephrology, gynaecology, respiration, and pain management. Its anti-malaria treatments in Africa have been able to influence the lives of more than 1 billion patients. Out of its 7 manufacturing units in India, the facilities at Paithan, Maharashtra, and Dahej, Gujarat, are approved by agencies like the Food and Drug Administration and the World Health Organisation.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 4333 13.6% | 3816 7.8% | 3540 15.4% | 3067 13.7% | 2697 26.4% | 2133 -3.0% | 2199 9.0% | 2018 10.9% | 1820 22.7% | 1483 22.0% | 1216 28.6% | 946 34.3% | 704 39.8% | 504 25.0% | 403 12.4% | 359 - |
| Net Operating Income (INR Cr) | 4209 12.45% | 3743 12.02% | 3341 15.62% | 2890 11.66% | 2588 25.91% | 2055 -3.31% | 2126 7.19% | 1983 13.37% | 1749 18.72% | 1474 21.95% | 1208 29.81% | 931 37.41% | 677 36.07% | 498 21.67% | 409 17.17% | 349 12.94% |
| Profit (INR Cr) | 816 38.8% | 588 -17.5% | 713 9.0% | 654 39.8% | 468 20.9% | 387 -17.4% | 469 -7.5% | 507 22.0% | 416 34.1% | 310 32.5% | 234 108.6% | 112 45.1% | 77 52.4% | 51 49.2% | 34 33.7% | 25 - |
| Assets (INR Cr) | 3646 5.6% | 3451 4.2% | 3313 8.6% | 3050 13.2% | 2694 17.4% | 2295 11.6% | 2056 30.7% | 1574 23.4% | 1275 38.5% | 921 26.3% | 729 39.2% | 524 4.2% | 503 19.1% | 422 2.2% | 413 1.4% | 407 - |
| Net Worth (INR Cr) | 3567 5.3% | 3388 3.8% | 3264 9.0% | 2996 15.3% | 2599 15.8% | 2245 10.0% | 2041 30.2% | 1568 31.6% | 1191 41.6% | 841 41.8% | 593 50.8% | 393 32.0% | 298 30.2% | 229 23.7% | 185 17.7% | 157 16.5% |
| Employee Cost (INR Cr) | 900 14.7% | 785 21.6% | 646 17.8% | 548 12.9% | 486 12.7% | 431 14.4% | 376 27.4% | 295 15.1% | 257 28.0% | 201 27.8% | 157 27.4% | 123 31.3% | 94 32.4% | 71 48.3% | 48 12.0% | 43 - |
| Interest Cost (INR Cr) | 7 | 6 | 10 | 8 | 12 | 1 | 0 | 1 | 5 | 6 | 9 | 19 | 15 | 18 | 20 | 24 |
| Cash & Bank Balance (INR Cr) | 131 | 331 | 212 | 210 | 205 | 101 | 93 | 70 | 43 | 137 | 60 | 46 | 11 | 12 | 15 | 8 |
| Total Debt (INR Cr) | 35 | 36 | 25 | 31 | 75 | 36 | 2 | 1 | 81 | 72 | 130 | 125 | 200 | 191 | 228 | 250 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 18.8% | 15.4% | 20.1% | 21.3% | 17.3% | 18.1% | 21.3% | 25.1% | 22.8% | 20.9% | 19.2% | 11.9% | 11.0% | 10.1% | 8.4% | 7.1% |
| Profit As % Of Assets | 22.4% | 17.0% | 21.5% | 21.4% | 17.4% | 16.9% | 22.8% | 32.2% | 32.6% | 33.7% | 32.1% | 21.4% | 15.4% | 12.0% | 8.2% | 6.2% |
| Profit As % Of Networth | 22.9% | 17.4% | 21.8% | 21.8% | 18.0% | 17.2% | 23.0% | 32.3% | 34.9% | 36.8% | 39.4% | 28.5% | 25.9% | 22.2% | 18.4% | 16.2% |
| Interest Cost to EBITDA % | 0.6% | 0.8% | 1.1% | 0.8% | 1.8% | 0.2% | 0.1% | 0.2% | 0.8% | 1.2% | 2.4% | 8.5% | 11.7% | 20.3% | 25.7% | 36.2% |
| Debt to Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.07 | 0.09 | 0.22 | 0.32 | 0.67 | 0.83 | 1.23 | 1.59 |
| RONW | 23.5% | 17.7% | 22.8% | 23.4% | 19.3% | 18.1% | 26.0% | 36.8% | 40.9% | 43.2% | 47.4% | 32.4% | 29.3% | 24.5% | 19.9% | 17.4% |
| ROCE | 31.6% | 22.2% | 28.9% | 31.6% | 27.1% | 23.7% | 34.3% | 45.6% | 51.4% | 56.0% | 54.1% | 38.2% | 23.0% | 17.8% | 14.4% | 14.9% |